Procter & Gamble (PG) stock is in focus after recent trading data showed modest gains over the past month and past 3 months, prompting investors to reassess the consumer staples giant’s current valuation.

At a share price of $148.45, Procter & Gamble’s recent 30 day share price return of 3.41% and year to date share price return of 4.70% point to relatively steady, rather than explosive, momentum. The 1 year total shareholder return, including dividends, is down 4.14%, leaving the longer term 5 year total shareholder return of 24.06% as the more resilient reference point for patient holders.

If Procter & Gamble’s recent moves have you reassessing your watchlist, this could be a good moment to broaden your search and uncover 20 top founder-led companies

With Procter & Gamble trading at $148.45 and indicators such as an estimated intrinsic discount of 19.84% and a 10.18% gap to analyst targets, the key question is clear: is there real value left here, or is the market already pricing in future growth?

Most Popular Narrative: 23% Overvalued

According to the most followed Procter & Gamble narrative, a fair value of $121.06 sits well below the current $148.45 share price, which sets up a clear valuation gap investors are weighing carefully.

Procter & Gamble, despite being within a very competitive industry, still has some competitive advantages shown in its higher operating margin above the ~20% mark and the Morning Star Wide Moat. In addition, the fact that the ROIC is double the Cost of Capital means its capital allocation is being well managed. Its solid Moodys Debt Rating along with the Low Uncertainty Morningstar rating maintains the company as a stable and reliable investment if the opportunity arises.

Want to see what justifies that gap between fair value and price? The narrative leans on steady revenue growth, robust margins and a premium future earnings multiple to get there.

Result: Fair Value of $121.06 (OVERVALUED)

However, Procter & Gamble’s recent 1 year total shareholder return decline and the 22.6% premium to this fair value estimate could challenge the overvaluation thesis.

Another View on Procter & Gamble’s Valuation

The user narrative leans heavily on a weighted blend of models that land Procter & Gamble at a fair value of $121.06, implying the stock is overvalued. Our earnings based measure points in a different direction. At 21.2x P/E, Procter & Gamble trades below the peer average of 25.9x and just under a fair ratio of 22.3x, which suggests less valuation stretch than the narrative implies. So which reference point should sit at the center of your own work on the stock?

To see what the numbers behind this earnings multiple imply in more detail, including where the ratio could move if sentiment shifts, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mixed sentiment around Procter & Gamble’s valuation and outlook, this is the moment to move quickly, review the underlying data yourself, and decide how the balance of risks and rewards stacks up through 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Procter & Gamble?

If Procter & Gamble has you thinking more critically about valuation and quality, do not stop here. Broaden your research now so you do not overlook stronger fits.

• Target stability by checking companies that score well on resilience and fundamentals through the 72 resilient stocks with low risk scores.
• Spot potential value by scanning for quality stocks trading below what their fundamentals might support using the 42 high quality undervalued stocks.
• Hunt for future standouts by reviewing the screener containing 19 high quality undiscovered gems before they sit firmly on everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.